235 related articles for article (PubMed ID: 28112422)
1. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.
Yang T; Liu Q; Lu M; Ma L; Zhou Y; Cui Y
Br J Clin Pharmacol; 2017 Jul; 83(7):1369-1379. PubMed ID: 28112422
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C
Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
Sutherland A; Naessens K; Plugge E; Ware L; Head K; Burton MJ; Wee B
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012555. PubMed ID: 30246876
[TBL] [Abstract][Full Text] [Related]
4. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
Chiu L; Chow R; Popovic M; Navari RM; Shumway NM; Chiu N; Lam H; Milakovic M; Pasetka M; Vuong S; Chow E; DeAngelis C
Support Care Cancer; 2016 May; 24(5):2381-2392. PubMed ID: 26768437
[TBL] [Abstract][Full Text] [Related]
6. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
Yoodee J; Permsuwan U; Nimworapan M
Crit Rev Oncol Hematol; 2017 Apr; 112():113-125. PubMed ID: 28325253
[TBL] [Abstract][Full Text] [Related]
11. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
Bosnjak SM; Dimitrijevic J; Djordjevic F
Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
[TBL] [Abstract][Full Text] [Related]
12. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?
Chiu L; Chow R; DeAngelis C; Lock M; Simone CB
Ann Palliat Med; 2021 Mar; 10(3):2540-2547. PubMed ID: 33440973
[TBL] [Abstract][Full Text] [Related]
13. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.
Vig S; Seibert L; Green MR
J Cancer Res Clin Oncol; 2014 Jan; 140(1):77-82. PubMed ID: 24173694
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of the Efficacy of 5 mg Olanzapine and Aprepitant in the Prevention of Multiple-Day Cisplatin Chemotherapy-Induced Nausea and Vomiting.
Liu G; Jin Y; Jiang Y; Zhao J; Jiang C; Zhang Z; Zhao L; Li H; Chen F; Wang J; Fan H; Li Z; Jia Y; Jin G; Li Q
Int J Clin Pract; 2022; 2022():5954379. PubMed ID: 36128262
[TBL] [Abstract][Full Text] [Related]
17. Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
He M; Xu R; Liu M; Zhang Y; Yi F; Wei Y; Liu Q; Zhang W
Ann Palliat Med; 2021 Apr; 10(4):4308-4319. PubMed ID: 33894731
[TBL] [Abstract][Full Text] [Related]
18. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
[TBL] [Abstract][Full Text] [Related]
20. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP
J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
